Gian Antonio Dompé is born in Bene Vagienna, Italy. From early childhood, he has a passion for chemical and pharmaceutical sciences, which is to lead him and his family into this business adventure.
Onorato Dompé (Gian Antonio's son) and his partner, Paolo Adami, found the Dompé-Adami laboratory in via Pantano, Milan, near the main city hospital Ca' Granda.
Onorato had previously studied chemistry and pharmacy at the Royal University of Turin and spent time in London,.
Onorato purchases the Farmacia Centrale located in piazza della Scala - possibly the most important pharmacy in Milan. Over the following years he expands, establishing pharmacies in piazza Missori, Milan, Palermo and Ponte Chiasso, Switzerland.
Onorato founds the Farmacie italo-inglesi, which operates according to British standards.
Their galenic formulations leads to a transformation in how pharmacies are run and a chain of shops are established in major cities across Italy.
The Dompé-Adami laboratory expands and moves to new premises in via Pantano 5, close to Ca' Granda, Milan's main hospital.
Onorato acquires a building in via San Martino 12, Milan. He lives here for the rest of his life, with his family and company, conducting experiments on new pharmaceutical preparations.
Onorato’s son Franco Dompé starts to turn his father's work into an industry, following his graduation in 1936 in Chemistry and Pharmacy at the University of Pavia. He establishes a laboratory in Via Bocconi 9, Milan. This is the start of Dompé farmaceutici.
Franco's company continues to grow despite the war, and he moves the company to via San Martino 12, the company’s current headquarters in Milan.
Dompé pharmaceuticals becomes known for the production of medicines in vials, establishing a major production plant, inaugurated in the presence of Monsignor Ildefonso Schuster, Cardinal of Milan.
The company sponsors and provides medical services to the Cortina d'Ampezzo Olympics. Over the following decades, innovative marketing includes launching promotional sea cruises for doctors and the concept of ‘product placement’ by arranging for Guaiacalcium cough medicine to be featured in a movie directed by Vittorio De Sica.
Sergio Dompé launches the company’s new strategy: investment in research and a focus on targeted therapeutic areas, covering anti-inflammatory, osteoarticular and respiratory areas.
Rita Levi Montalcini receives the Nobel Prize in Medicine for her discovery of the Nerve Growth Factor (NGF).
Credit to: "Presidenza della Repubblica"
Dompé Biotec is born, a center of reference in Italy and Europe for biotechnological innovation.
The Dompé production hub is launched in L’Aquila, Italy, specializing in the production of oral, liquid and granular formulations, ensuring national and international supplies of proprietary products.
In L’Aquila, Dompé creates a biotech plant for the production of recombinant proteins in the treatment of rare diseases.
In Italy, Biogen Dompé, a joint venture between Biogen Idec and Dompé, is entirely dedicated to finding new therapeutic solutions for multiple sclerosis. Its goal is to offer innovative biotechnology drugs with a high therapeutic profile.
Amgen Dompé is established, a joint venture between Amgen and Dompé, focused on the development of drugs for oncology and nephrology.
Dompé creates the Q-rare division, with the goal of offering innovative therapeutic solutions for the treatment of diseases that are still without a cure.
Dompé acquires the rights to develop, produce and market the Nerve Growth Factor (NGF) protein for the treatment of neurotrophic keratitis, a rare eye disease.
This is the first therapeutic application from the studies that won Rita Levi Montalcini the Nobel Prize.
Dompé also acquires more than 30% of Philogen, a biotech company involved in the development of oncological drugs
Dompé increases potential for biotechnology research and production with the expansion of the L’Aquila biotech plant
Dompé opens new headquarters in Milan and completes the acquisition of Anabasis - the Italian company developing innovative treatments for eye diseases based on studies on NGF.
Phase III clinical trials in Europe and the US begin to assess Reparixin’s effectiveness in improving the efficiency of pancreatic island allogeneic transplantation.
The first international phase I/II clinical trial of the use of recombinant human NGF in the treatment of neurotrophic keratitis is started. 37 European centres are involved.
Dompé announces that rhNGF has been designated an orphan drug for the treatment of retinitis pigmentosa by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
A phase II/III study is started to assess the efficacy and safety profile of Reparixin in autologous pancreatic islet transplantation. The trial is conducted in the US.
Enrolment of Dompé’s first Phase III trial with Reparixin for patients undergoing pancreatic islet transplantations is closed.
Dompé launches a New York subsidiary to coordinate the research and development into new drugs for the treatment of pathologies in ophthalmology, oncology and transplantation.
The European Medicines Agency (EMA) Orphan Drugs Committee designates Dompe’s experimental biotechnology molecule rhNGF, developed as an orphan drug for the treatment of neurotrophic keratitis.
Enrolment starts for phase II of the clinical trial of fRida in patients with metastatic triple negative breast cancer.
The European Medicines Agency (EMA) approves the request for authorisation to market Cenegermin eye drops (Oxervate®), developed for the treatment of moderate and severe neurotrophic keratitis in adults.
Dompé takes over the Pharma division of Gruppo farmaceutico Bracco.
Dompé launches Dompé Primary, to develop and distribute ethical drugs and OTC products, dietary supplements, medical devices and cosmetics in a number of therapeutic fields - cardiovascular, gastrointestinal, paediatric, neurological, endocrinological, urological, ophthalmic, stomatological and respiratory diseases - and in the areas of integration of vitamins and minerals and of personal hygiene.
In July, the European Commission authorizes marketing of rhNGF-based eye drops. This is the first biotech drug authorized for the treatment of a rare ophthalmic disease.
Dompe’ innovation in rhNGF is granted Fast Track, Breakthrough Therapy Designation and Priority Review statuses by the US Food and Drug Administration (FDA).
In August, the FDA authorizes the commercialization of rhNGF in the US.
In August, the NMPA (National Medical Products Administration) authorizes the commercialization of rhNGF in China.